Table 1.
Study patient population distributed by clinical category, age, sex and assayed immune parameters.
| Clinical category | Total Patients | Age mean±SD (range) | % female | Assayed immune parameters | ||||
|---|---|---|---|---|---|---|---|---|
| Cell Subset | Plasma Cytokines | Tetramer | T-cell Function Assay | RNA array | ||||
| Benign Nevi | 34 | 51±12 (21–71) | 68 | 26 | 34 | 7 | 2 | 0 |
| Atypical/Dysplastic | 25 | 52±16 (25–84) | 44 | 22 | 16 | 11 | 1 | 0 |
| In situ melanoma | 36 | 61±16 (26–84) | 36 | 30 | 35 | 16 | 3 | 0 |
| Stage I | 45 | 54±17 (21–82) | 44 | 36 | 44 | 16 | 4 | 0 |
| Stage II | 16 | 55±17 (22–81) | 44 | 11 | 12 | 9 | 0 | 0 |
| Stage III | 16 | 53±19 (23–83) | 44 | 14 | 16 | 6 | 1 | 0 |
| Stage IV | 37 | 56±14 (28–85) | 43 | 32 | 30 | 27 | 16 | 24 |